Understand the source comparison
How to Stop Sugar Cravings with Peptides: GLP-1 vs Dual-Agonist Comparison
Semaglutide (GLP-1 agonist) GLP-1 receptor activation, delayed gastric emptying, ghrelin suppression 52% reduction in craving frequency at 12 weeks (STEP trials) Weekly injection 2–4 weeks to therapeutic effect Best-studied option with longest safety data. Fiv
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (GLP-1 agonist)
- GLP-1 receptor activation, delayed gastric emptying, ghrelin suppression
- 52% reduction in craving frequency at 12 weeks (STEP trials)
- Weekly injection
- 2–4 weeks to therapeutic effect
- Best-studied option with longest safety data. Five-day half-life allows consistent weekly dosing without plasma fluctuation
- Tirzepatide (GLP-1/GIP dual agonist)
- GLP-1 + GIP receptor co-activation, improved insulin sensitivity, reduced glucose variability
- 63% reduction in food cravings at 72 weeks (SURMOUNT-1)
- 3–5 weeks to peak effect
- Superior craving suppression vs semaglutide, but shorter safety track record. GIP agonism amplifies metabolic benefit beyond GLP-1 alone
- Liraglutide (GLP-1 agonist)
- GLP-1 receptor activation, satiety signaling via vagal afferents
- 38% reduction in sweet food preference (observational studies)
- Daily injection
- 5–7 days to therapeutic effect
- Requires daily dosing due to 13-hour half-life. Missing a dose resets progress; less convenient but faster onset than weekly options